Granulocyte–Macrophage Colony-stimulating Factor

Sensitive and Receptor-mediated Regulation by 1,25-Dihydroxyvitamin D_3 in Normal Human Peripheral Blood Lymphocytes

A. Tobler, J. Gasson, H. Reichel,* A. W. Norman,* and H. P. Koeffler

*Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles Medical Center, Los Angeles, California 90024; and *Department of Biochemistry, University of California, Riverside, California 92521*

Abstract

We show that 1,25-dihydroxyvitamin D_3 (1,25[OH]$_2$D$_3$), the most hormonally active metabolite of vitamin D_3, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte–macrophage colony-stimulating factor (GM-CSF). The regulation of GM-CSF expression is seen in both normal human mitogen–activated T lymphocytes and T lymphocytes from a line (S-LB1) transformed with human T cell lymphotropic virus 1 (HTLV-1). In contrast, cells from a HTLV-1 transformed T lymphocyte line (Ab-VDR) established from a patient with vitamin D–resistant rickets type II with undetectable 1,25(OH)$_2$D$_3$ cellular receptors are resistant to the action of 1,25(OH)$_2$D$_3$. Inhibition of GM-CSF expression by 1,25(OH)$_2$D$_3$ can occur independently of interleukin 2 regulation and is probably mediated through cellular 1,25(OH)$_2$D$_3$ receptors. We conclude that 1,25(OH)$_2$D$_3$ may be important in the physiology of hematopoiesis.

Introduction

Evidence is accumulating that the hormonally active metabolite of vitamin D_3, 1,25-dihydroxyvitamin D_3 (1,25[OH]$_2$D$_3$),[1] might play an important role as an immunohematopoietic regulatory hormone (reviewed in references 1, 2). Specific 1,25(OH)$_2$D$_3$ receptors are present in normal human mitogen–activated and malignant T and B lymphocytes and myeloid cells (3, 4). 1,25(OH)$_2$D$_3$ enhances the in vitro differentiation of normal and leukemic myeloid stem cells towards macrophages (5–7). 1,25(OH)$_2$D$_3$ inhibits proliferation and suppresses interleukin 2 (IL-2) synthesis of mitogen-activated T lymphocytes (8–11). Human macrophages activated by γ-interferon synthesize 1,25(OH)$_2$D$_3$ (12, 13).

Address reprint requests to Dr. A. Tobler, UCLA School of Medicine, Division of Hematology/Oncology, 11-240 Factor Building, Los Angeles, CA 90024.

Received for publication 29 July 1986 and in revised form 23 December 1986.

1. *Abbreviations used in this paper:* 1,25(OH)$_2$D$_3$, 1,25-dihydroxyvitamin D_3; CM, conditioned medium; ED_{50}, dose effective in achieving half-maximal response; GM-CFC, granulocyte–macrophage colony-forming cells; GM-CSF, granulocyte–macrophage colony-stimulating factor; HTLV-1, human T cell lymphotropic virus 1; IL-2, interleukin 2; PBL, normal human peripheral blood lymphocytes; PHA, phytohemagglutinin.

J. Clin. Invest.

0021-9738/87/06/1700/06 $1.00
Volume 79, June 1987, 1700–1705

Survival, proliferation, and differentiation of hematopoietic cells are dependent on colony-stimulating factors (CSF). The granulocyte–macrophage CSF (GM-CSF), which is synthesized by activated T lymphocytes, has been cloned (14, 15). Recombinant and natural GM-CSF possess multilineage colony-stimulating activity (16, 17) and also enhances mature cell function of neutrophils and eosinophils (18, 19). We report here that 1,25(OH)$_2$D$_3$ sensitively and specifically inhibits the expression of GM-CSF in T lymphocytes.

Methods

Compounds. The vitamin D_3 metabolites (1,25[OH]$_2$D$_3$, 1,24,25-[OH]$_3$D$_3$, and 25[OH]D$_3$) were a generous gift from Dr. M. Uskokovic, Hoffmann-La Roche, Inc., Nutley, NJ. The compounds were dissolved in 100% ethanol to a stock concentration of 1×10^{-3} M and stored at −20°C. The various concentrations (10^{-11}–10^{-7} M) were obtained by diluting the stock solutions in phosphate-buffered saline (PBS). The concentration of ethanol did not exceed 0.1%. Recombinant human IL-2 was generously provided by Jürgen Besemer (Sandoz Ltd., Vienna, Austria). Phytohemagglutinin (PHA) (Wellcome Diagnostics, Datford, England) was used in a final concentration of 0.5%.

Cells and liquid culture assay. The human cell lines S-LB1 (20), Ab-VDR (H. P. Koeffler and A. W. Norman, unpublished observations), HL-60 (21), and KG-1 (22) were maintained in suspension culture T flask (Miles Laboratories Inc., Naperville, IL), containing alpha medium (Flow Laboratories, Inc., Rockville, MD) and 10% fetal calf serum (FCS) (Irvine Scientific, Santa Ana, CA) in a humidified atmosphere of 7% CO_2. The medium was changed two times a week.

Human peripheral blood lymphocytes (PBL) and human bone marrow cells were obtained from normal volunteers and isolated by Ficoll-Hypaque density gradient (1.077 g/ml) (Sigma Chemical Co., St. Louis, MO). Monocytes were removed from PBL by their ability to adhere to plastic for 6 h. The PBL and the human HTLV-1 immortalized T lymphocyte cell lines (S-LB1, Ab-VDR) were cultured for 2 d at 1×10^6 cells/ml in alpha medium–supplemented with 10% FCS in the presence of the various additives (vitamin D_3 compounds, PHA, IL-2) at 37°C in a humidified atmosphere of 7% CO_2. The conditioned media (CM) were stored at 4°C. Cell viability was not affected in the various experimental protocols, as determined by trypan blue exclusion.

Colony formation assay by two-layer agar techniques. The underlayer was plated in 1-ml portions in 35-mm petri dishes (Miles Laboratories Inc.) containing 0.5% agar, alpha medium, 16% FCS and CM from PBL as a source of CSF. CM obtained from the human T lymphocyte Mo cell line was used for control purpose at a final concentration of 1.5% (23). The overlayer contained the GM-CSF responder cells (bone marrow, KG-1), alpha medium, 16% FCS, penicillin, streptomycin, and 0.3% agar. The culture dishes were incubated at 37°C in a humidified atmosphere with 7% CO_2 for 10–13 d. Colonies (> 40 cells) were counted using an inverted microscope.

Complementary DNA (cDNA) probes, Northern blot technique. The IL-2 cDNA was a generous gift from S. Clarke, Genetics Institute, Boston, MA (24). The IL-2 receptor cDNA was kindly provided by T. Nikaido (25). The IL-2 and the IL-2 receptor probes were [^{32}P]-labeled by the

random priming method as described (26). The GM-CSF probes were [^{32}P]-labeled by nick translation (27).

For cytoplasmic RNA, freshly harvested cells were suspended in hypotonic buffer (10 mM Tris-HCl [pH 7.4], 1 mM KCl, 3 mM $MgCl_2$) and were lysed with Nonidet P-40 (0.3%). Nuclei were removed by centrifugation. Cytoplasmic RNA was extracted by the phenol/chlorofom method as essentially described (28) and quantified by absorbance at 260 nm. Samples were denatured at 65°C for 10 min, size-separated by an agarose formaldehyde gel (1% agarose [Bethesda Research Laboratories, Gaithersburg, MD], 50 mM Na acetate, 10 mM Na_2 EDTA, 200 mM MOPS, and 2.2 M formaldehyde), and transferred to a nylon membrane filter (ICN Biomedicals Inc., Irvine, CA). Filters were dried, baked at 80°C in vacuo for 2 h, and then prehybridized for 16–24 h. Hybridizations with [^{32}P]-labeled cDNA (1×10^6 cpm/ml) were performed at 42°C for 16–24 h in a solution containing 50% (vol/vol) formamide, 2× SSC (1× SSC is 150 mM NaCl, 15 mM sodium citrate), 5× Denhardts (1× Denhardts is 0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine serum albumin), 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, 10% (vol/vol) dextran sulfate (500,000 mol wt) (Sigma Chemical Co.), and 100 μg/ml salmon sperm DNA (Sigma Chemical Co.). Filters were washed to a stringency of 0.1× SSC, 1% SDS at 65°C and exposed for 24–48 h at −70°C to XAR-5 film (Eastman Kodak Co., Rochester, NY).

Measurement of [^{14}C]uridine incorporation. S-LB1 cells (1×10^6/ml) were exposed in 24-well plates (Miles Laboratories Inc.) in quadruplicates for various durations (0, 6, 48 h) to $1,25(OH)_2D_3$ (10^{-8} M). Cells were pulsed with 0.5 μCi of [^{14}C]uridine (New England Nuclear, Boston, MA) for 2 h at 37°C, washed twice in PBS, precipitated in 5% trichloroacetic acid (TCA) for 10 min, washed twice in 5% TCA, and heated at 80°C for 60 min. 200 μl of each sample was counted by liquid scintillation.

Measurement of [^{3}H]thymidine incorporation. PBL (1×10^6/ml) were cultured in the presence of 0.5% PHA and $1,25(OH)_2D_3$ (10^{-7} M) in equal volumes (100 μl) in triplicates in 96-well plates (Corning Glass Works, Corning, NY). After 48 h, cells were pulsed with 1 μCi of [^{3}H]thymidine (ICN Biomedicals Inc.) for 5 h at 37°C and harvested into glass filter fiber with a Mash II cell harvester (Skatron, Inc., Sterling, VA) and counted by liquid scintillation.

Results

Modulation of GM-CSF protein levels by $1,25(OH)_2D_3$ and influence of IL-2 on GM-CSF expression in peripheral blood lymphocytes: dose response. The PBL (1×10^6/ml) were cultured in the presence of increasing concentrations of $1,25(OH)_2D_3$ (10^{-11}–10^{-7} M) and PHA (0.5%). After 2 d, CSF activity of the CM was assayed for stimulation of clonal growth of both normal human granulocyte–macrophage colony-forming cells (GM-CFC) and the human myeloblastic leukemic cell line KG-1 (Fig. 1 *A*). Clonal growth of both GM-CFC and KG-1 cells is dependent on CSF (22). We found that $1,25(OH)_2D_3$ decreased levels of GM-CSF protein in a dose-dependent fashion with a 50% reduction of CSF activity (ED_{50}) at $\sim 5 \times 10^{-10}$ M $1,25(OH)_2D_3$ when tested on clonal growth of GM-CFC and KG-1 cells. Control dishes containing no $1,25(OH)_2D_3$ formed 127±8 (±SD) GM-CFC and 62±10 (±SD) KG-1 colonies. No difference in colony formation could be observed when $1,25(OH)_2D_3$ (10^{-8} M) was added directly to the culture dishes containing CM of PHA-activated PBL compared with the control dishes containing CM of PHA-stimulated PBL only.

Prior studies showed that $1,25(OH)_2D_3$ decreased proliferation and IL-2 synthesis by PBL (8–11). We examined, therefore, whether IL-2 might affect the modulation of GM-CSF production by $1,25(OH)_2D_3$ in lymphocytes (Fig. 1 *A*). The PBL were cultured for 48 h in the presence of a high concentration of recombinant human IL-2 (200 ng/ml/10^6 cells), $1,25(OH)_2D_3$ (10^{-11}–10^{-7} M) and PHA (0.5%); the CM was assayed for stimulation of GM-CFC. We found that the addition of IL-2 to the cultures slightly blunted but did not reverse the inhibitory action of $1,25(OH)_2D_3$ on GM-CSF protein activity. The IL-2 alone



Figure 1. Modulation of GM-CSF expression by $1,25(OH)_2D_3$ in PBL. Dose-response studies (*A–C*): (*A*) Regulation of GM-CSF protein production. PBL were cultured for 48 h in the presence of PHA and $1,25(OH)_2D_3$. GM-CSF activity of the CM was tested by measuring clonal growth of both a normal human GM-CFC (○) and a leukemic myeloblastic cell line KG-1 (■). In a parellel series of experiments, recombinant IL-2 (200 ng/ml) was added to the cultures and the CM was assayed on GM-CFC (●). The IL-2 alone had no effect on clonal growth. (*B* and *C*) Regulation of GM-CSF mRNA levels (Northern blots). PBL were incubated for 48 hours with PHA and $1,25(OH)_2D_3$. When probed with GM-CSF cDNA, a single band was detected at 0.9 kb consistent with the known length of GM-CSF mRNA (*B*). The same Northern blot was reprobed with IL-2 receptor cDNA, as a control (*C*). Two bands were observed at 1.4 and 3.5 kb consistent with IL-2 receptor mRNA. Time-response studies (*D* and *E*): (*D*) Regulation of GM-CSF protein production. PBL were exposed to PHA and for various durations (12–48 h) to $1,25(OH)_2D_3$ (10^{-8} M). All time points were harvested after 48 h. GM-CSF activity was assayed on GM-CFC. (*E*) Regulation of GM-CSF mRNA levels (Northern blot). PHA-activated PBL were cultured for various durations (6–48 h) with $1,25(OH)_2D_3$ (10^{-8} M). PBL at all time points were harvested after 48 h. Each experiment in *A* and *D* represents the mean±SD from three independent experiments with PBL from three different donors. RNA was extracted as described in Methods. Each lane in *B, C,* and *E* contains 30 μg cytoplasmic RNA. Results are expressed as a percent reduction of mRNA accumulation by $1,25(OH)_2D_3$ as compared with the untreated control sample not exposed to $1,25(OH)_2D_3$ (determined by densitometry on different exposures of preflashed autoradiograms).

had no effect on clonal growth of GM-CFC. CM from control cultures (PHA 0.5%, no IL-2, no $1,25[OH]_2D_3$) stimulated a mean 243±8 (±SD) GM-CFC per 2×10^5 mononuclear bone marrow cells.

Modulation of GM-CSF mRNA levels by $1,25(OH)_2D_3$ in PBL: dose response. The modulation of GM-CSF mRNA levels of PBL cultured with various concentrations of $1,25(OH)_2D_3$ was determined by Northern blot analysis (Fig. 1 *B*). The PBL were pooled from seven different donors, exposed for 2 d to increasing concentrations of $1,25(OH)_2D_3$ (10^{-11}–10^{-8} M) and PHA (0.5%) and the mRNA was extracted. A single band of hybridization was detected at 0.9 kb, which is consistent with GM-CSF mRNA (14, 15). The $1,25(OH)_2D_3$ reduced mRNA accumulation in a dose-dependent manner with an ED_{50} of $\sim 5 \times 10^{-11}$ M as determined by densitometry reading. The same Northern blot was washed and reprobed with a human cDNA for the IL-2 receptor gene to exclude a nonspecific degradation of mRNA (Fig. 1 *C*). Two classes of IL-2 receptor mRNA could be observed at 1.4 and 3.5 kb, which is in accordance with previously reported data (25). No significant change of IL-2 receptor mRNA (1.4-kb band) could be detected.

Modulation of GM-CSF protein and mRNA levels by $1,25(OH)_2D_3$ in PBL: time response. We examined whether $1,25(OH)_2D_3$ might be able to down-regulate protein and mRNA levels of GM-CSF in PBL already activated by PHA (Fig. 1, *D* and *E*). For all time points, the PBL were exposed for 48 h to PHA (0.5%). The $1,25(OH)_2D_3$ (10^{-8} M) was added to the cultures at times 0, 24, 36 h for the protein studies, and 0, 24, 42 h for the mRNA studies. Control samples were stimulated by PHA alone. We found that a 12-h exposure to $1,25(OH)_2D_3$ inhibited GM-CSF protein production by $\sim$ 50% in PBL previously activated with PHA for 36 h (Fig. 1 *D*); and a 6-h exposure to $1,25(OH)_2D_3$ was sufficient to reduce mRNA levels of GM-CSF by $\sim$ 50% in PBL previously activated for 42 h (Fig. 1 *E*).

Regulation of GM-CSF mRNA levels by $1,25(OH)_2D_3$ in a HTLV-1 immortalized T lymphocyte line (S-LB1). We performed a parallel series of experiments using a human T lymphocyte line (S-LB1) established by infection of normal human T lymphocytes with HTLV-1 (20). These cells constitutively synthesize GM-CSF and express high levels of IL-2 receptors (29, 30). S-LB1 cells were exposed for 48 h to increasing concentrations of $1,25(OH)_2D_3$ (10^{-11}–10^{-7} M) (Figs. 2 *A*). The $1,25(OH)_2D_3$ decreased GM-CSF mRNA levels in a dose-dependent fashion as shown on the Northern blot, and a 50% reduction of mRNA occurred at $\sim 2.5 \times 10^{-11}$ M. Time-response experiments showed that a 50% decrease of GM-CSF mRNA accumulation occurred within 6 h of exposure of S-LB1 cells to $1,25(OH)_2D_3$ (10^{-8} M) (Fig. 2 *B*). For control purpose, the same samples were reprobed with IL-2 receptor cDNA (Fig. 2 *C*). Only a slight change of the IL-2 receptor mRNA levels (1.4-kb band) could be detected when S-LB1 cells were exposed to $1,25(OH)_2D_3$ (10^{-8} M), as compared to the marked decrease of GM-CSF mRNA levels.

Receptor-mediated modulation of GM-CSF expression by vitamin D_3 seco-steroids. We first studied the ability of other metabolites of vitamin D_3 to regulate the accumulation of GM-CSF mRNA by S-LB1 cells (Fig. 3 *A*). The S-LB1 cells were cultured for 48 h with different vitamin D_3 metabolites (10^{-8} M). The rank order of potency ($1,25[OH]_2D_3 > 1,24,25[OH]_3D_3 > 25[OH]D_3$) of the metabolites to affect accumulation of GM-CSF mRNA paralleled the affinity of the metabolites to bind to the $1,25(OH)_2D_3$ cellular receptors in other tissues (31). Secondly,



Figure 2. Modulation of GM-CSF mRNA levels by $1,25(OH)_2D_3$ in HTLV-1–immortalized T lymphocytes derived from a normal individual (S-LB1). (*A*) Dose-response experiments. S-LB1 cells were exposed for 48 h to $1,25(OH)_2D_3$. Analysis was performed by Northern blot technique with 30 μg cytoplasmic RNA per lane. (*B* and *C*) Time-course experiments (Northern blot). S-LB1 cells were cultured for various durations (0.5–48 h) with $1,25(OH)_2D_3$ (10^{-8} M). Each lane contains 20 μg RNA. As a control, the same samples were reprobed with IL-2 receptor cDNA (*C*). Two bands were observed at 1.4 and 3.5 kb consistent with IL-2 receptor mRNA. Analysis was performed as described in Fig. 1. A single band at 0.9 kb (*A* and *C*) was detected when probed with GM-CSF cDNA.

we established a HTLV-1 immortalized T lymphocyte cell line derived from a patient with vitamin D–resistant rickets type II (Ab-VDR). Vitamin D–resistant rickets II is a heterogenous group of syndromes characterized by a decreased or absent ability of $1,25(OH)_2D_3$ to bind to its cellular receptor (1, 32). Exposure of the Ab-VDR cells to $1,25(OH)_2D_3$ (10^{-8} M, 10^{-10} M) for 48 h had little effect on GM-CSF mRNA accumulation (reduction of mRNA of $\sim$ 15% compared with control samples, as determined by densitometry) (Fig. 3 *B*). These results are consistent with Ab-VDR cells having undetectable $1,25(OH)_2D_3$ cellular receptors, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koeffler and A. W. Norman, unpublished observations).

Influence of IL-2 on the expression of GM-CSF by S-LB1 cells. Previous studies suggested that most HTLV-1–transformed T lymphocytes do not synthesize IL-2 (33). We probed S-LB1 mRNA with a human cDNA for IL-2 (Fig. 3 *C*). The PHA-stimulated PBL were used as a positive control and the human promyelocytic cell line HL-60 as a negative control. A single band could be detected at 0.9 kb in PHA-activated lymphocytes consistent with IL-2 mRNA (24). However, no IL-2 mRNA could be detected in S-LB1 cells and yet cells from the same passage were regulated very sensitively by $1,25(OH)_2D_3$ (Fig. 2 *A*).

Total RNA synthesis by S-LB1 cells in the presence of $1,25(OH)_2D_3$ ($[^{14}C]$uridine incorporation). To further examine whether $1,25(OH)_2D_3$ influences total RNA synthesis in lymphocytes, we exposed S-LB1 cells (1×10^6/ml) for 0, 6 and 24 h to $1,25(OH)_2D_3$ (10^{-8} M) and measured [^{14}C]uridine incorporation into TCA precipitable counts (Table I). A 6-h exposure



Figure 3. (*A*) Regulation of GM-CSF mRNA by different vitamin D metabolites in S-LB1 cells (Northern blot). S-LB1 cells were exposed for 48 h to different vitamin D metabolites (10^{-8} M). (*B*) Regulation of GM-CSF mRNA by $1,25(OH)_2D_3$ in the HTLV-1–immortalized T lymphocyte line Ab-VDR which was derived from a patient with vitamin D–resistant rickets, type II (Northern blot). S-LB1 cells (*S*) and Ab-VDR cells (*V*) were cultured for 48 h in the presence of $1,25(OH)_2D_3$ (10^{-8} and 10^{-10} M). (*C*) Analysis of IL-2 mRNA in S-LB1 cells (Northern blot). Using an IL-2 cDNA probe, a single band could be detected from RNA of PHA-activated PBL at 0.9 kb (*Lymph,* positive control) consistent with IL-2 mRNA; RNA from HL-60 promyelocytic leukemic cells was used as a negative control. Analysis was performed as described in Fig. 1 and Methods. Each lane in *A–C* contains 30 μg RNA. A single band at 0.9 kb (*A* and *B*) was detected when probed with GM-CSF cDNA.

to $1,25(OH)_2D_3$ had almost no effect on RNA synthesis. A 24-h exposure to $1,25(OH)_2D_3$ decreased the incorporation of [^{14}C]uridine TCA precipitable counts by ~ 33% as compared with the control sample not treated with $1,25(OH)_2D_3$.

Table I. [^{14}C]*Uridine Incorporation in S-LB1 Cells Exposed for Various Durations to* $1,25(OH)_2D_3$

Time exposed to $1,25(OH)_2D_3$	Experiments		Mean percent inhibition, nos. 1 and 2
	No. 1	No. 2	
h	*cpm × 10⁴ (%)*	*cpm × 10⁴ (%)*	
0 (control)	9.8±0.17 (0)	1.26±0.03 (0)	0
6	9.6±0.04 (2)	1.17±0.03 (6)	4
24	6.4±0.04 (33)	0.85±0.03 (32)	33

[^{14}C]Uridine incorporation as a measurement of RNA metabolism. S-LB1 cells (1×10^6/ml) were cultured in the presence of either ethanol control (≤ 0.01% ethanol) or $1,25(OH)_2D_3$ (10^{-8} M). Results represent mean±SD of quadruplicate cultures of two independent experiments (Nos. 1 and 2). Numbers in parentheses denote percentage of inhibition as compared with control sample treated with no $1,25(OH)_2D_3$. Analysis was performed as described in Methods.

Proliferation studies ([^{3}H]thymidine incorporation). We measured the effect of $1,25(OH)_2D_3$ (10^{-7} M) on PHA-activated PBL by measuring [^{3}H]thymidine incorporation. After 48 h in culture, PHA-activated PBL incorporated 11,911±4,446 cpm/10^6 cells. Treatment with $1,25(OH)_2D_3$ (10^{-7} M) for 48 h resulted in a statistically insignificant ($P > 0.5$) decrease of [^{3}H]thymidine incorporation into PBL (8,728±2,097 cpm/10^6 cells), representing a 16.7% inhibition as compared with the control samples not treated with $1,25(OH)_2D_3$. The results represent the mean±SD for nine incubations.

Discussion

We report in the present in vitro study that $1,25(OH)_2D_3$, the most active metabolite of vitamin D_3, is a potent inhibitor of the expression of the hematopoietic growth factor GM-CSF in PHA-activated normal human peripheral blood lymphocytes (PBL). The $1,25(OH)_2D_3$ regulated both protein and mRNA accumulation of GM-CSF; and this down-regulation occurred at concentrations close to those in vivo (Fig. 1). The recent reports that activated macrophages synthesize $1,25(OH)_2D_3$ (12, 13) further indicate that $1,25(OH)_2D_3$ might interact with GM-CSF production at a local level. Our time-response studies indicate that $1,25(OH)_2D_3$ can influence GM-CSF expression by PBL also in later stages of mitogenesis (Fig. 1 *E*). The concentrations of $1,25(OH)_2D_3$ achieving half-maximal response (ED_{50}) were 5×10^{-11} M and 5×10^{-10} M for GM-CSF mRNA levels and GM-CSF protein activity, respectively. These differences in the ED_{50} can be explained by the greater sensitivity and specificity of the RNA blot technique compared with the clonogenic assay in soft agar. In the clonogenic assay, CM from PHA-stimulated lymphocytes was used which, besides GM-CSF, also contains an admixture of other growth factors, including interleukin 3 and other lymphokines. These additional factors may have decreased both the sensitivity and specificity of the clonogenic assay. Similar to PBL, the $1,25(OH)_2D_3$ sensitively inhibited mRNA accumulation of GM-CSF by the HTLV-1 immortalized T lymphocytes (S-LB1) derived from a normal individual (19) (Fig. 2 *A*).

The $1,25(OH)_2D_3$ did not markedly affect mRNA levels for the IL-2 receptor in either the PHA-activated PBL or S-LB1 cells which constitutively produce high levels of IL-2 receptors (Figs. 1 *C*, 2 *C*). This suggests that $1,25(OH)_2D_3$ does not non-specifically decrease levels of mRNA in lymphocytes. The $1,25(OH)_2D_3$ inhibited total cellular RNA synthesis in S-LB1 cells as determined by incorporation of [^{14}C]uridine into TCA precipitable counts (Table I). This inhibition of total RNA, however, was much less pronounced and less rapid as compared with the decrease in GM-CSF mRNA in the same cells (4 and 52% inhibition, respectively, after exposure for 6 h to $1,25[OH]_2D_3$ [Fig. 2 *B*, Table I]).

Several recent reports suggested that $1,25(OH)_2D_3$ may be capable of immunoregulation similar to the glucocorticoids. Tsoukas et al. showed that $1,25(OH)_2D_3$ inhibited the lymphocyte growth–promoting factor IL-2 by PBL (10). Studies using different vitamin D_3 metabolites suggested that the effect of $1,25(OH)_2D_3$ was probably mediated by a specific receptor. Likewise, Rigby et al. demonstrated that $1,25(OH)_2D_3$ was a potent inhibitor of PHA-induced lymphocyte proliferation, achieving a 70% inhibition of [^{3}H]thymidine incorporation after 72 h in culture (9). Another study also showed that $1,25(OH)_2D_3$

inhibited the proliferation and IL-2 protein production by helper T lymphocytes (8). Similarly, $1,25(OH)_2D_3$ decreased the antigen-induced proliferation and IL-2 protein synthesis by cloned Ia-restricted T cell hybridomas after 24 h in culture (11). Taken together, these studies revealed a possible immunoregulatory role for $1,25(OH)_2D_3$ that has not previously been appreciated.

The $1,25(OH)_2D_3$ receptors are not present in resting T lymphocytes, but do appear 24 h after mitogenic stimulation (4). The HTLV-1–immortalized T-cell lines constitutively express $1,25(OH)_2D_3$ receptors. Our experiments using different vitamin D_3 metabolites suggest that the inhibition of the GM-CSF expression by $1,25(OH)_2D_3$ is most likely mediated through specific cellular receptors (Fig. 3 *A*). The potency of these compounds to reduce mRNA levels of GM-CSF paralleled their known affinity to bind to the specific cellular receptor in other tissues (31). Furthermore, our results are in accordance with the reported dissociation constant of 3.8×10^{-10} M for $1,25(OH)_2D_3$ by PHA-activated PBL (3). A more direct evidence for this assumption of a receptor-mediated mechanism relies on our study using a HTLV-1–immortalized T lymphocyte line (Ab-VDR) that was derived from a patient with vitamin D–resistant rickets type II. Exposure of Ab-VDR cells to $1,25(OH)_2D_3$ resulted in only a small decrease of GM-CSF mRNA levels compared with the marked decrease in S-LB1 cells (Fig. 3 *B*). These results are consistent with our observation that Ab-VDR cells have undetectable $1,25(OH)_2D_3$ receptors, whereas the $1,25(OH)_2D_3$-sensitive S-LB1 cells display 13 fmol $1,25(OH)_2D_3$ receptors/10^6 cells, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koeffler and A. W. Norman, unpublished observations). The fact that Ab-VDR cells responded at all to $1,25(OH)_2D_3$ suggests that either these cells have a low number of receptors not detectable by the present techniques or very high concentrations of $1,25(OH)_2D_3$ can affect all cells independent of expression of $1,25(OH)_2D_3$ receptors. Studies are currently under way to analyze the $1,25(OH)_2D_3$ receptors in these cells by using a specific cDNA probe for this hormone receptor. Koren et al. recently reported that peripheral blood mononuclear cells from patients with vitamin D–resistant rickets type II do not express $1,25(OH)_2D_3$ receptors, even after mitogenic stimulation (32). Moreover, proliferation of these lymphocytes could not be inhibited after a 72-h exposure to $1,25(OH)_2D_3$, in contrast to the normal cells.

Because prior studies showed that $1,25(OH)_2D_3$ inhibited the production of IL-2 (9, 10, 34), we questioned whether $1,25(OH)_2D_3$ might mediate its inhibitory effect on the expression of GM-CSF indirectly through a down-regulation of IL-2 production. Addition of very high concentrations of IL-2 (200 ng/ml) slightly abrogated but did not reverse the inhibition of GM-CSF protein production by $1,25(OH)_2D_3$ in PBL (Fig. 1 *A*). Furthermore, we observed that S-LB1 cells did not express IL-2 mRNA (Fig. 3 *C*). This T-cell line, therefore, provided an unusual tool to study our assumption of a possible IL-2–independent regulation of GM-CSF expression by $1,25(OH)_2D_3$. Our dose-response and time-course experiments clearly showed that $1,25(OH)_2D_3$ sensitively inhibited GM-CSF mRNA levels by S-LB1 cells in an IL-2–free system (Fig. 2, *A* and *B*). Taken together, our experiments suggest that $1,25(OH)_2D_3$ can regulate independently of IL-2 the expression of a lymphokine in transformed T lymphocytes. The effect of $1,25(OH)_2D_3$ on normal human PBL seems to be mostly but not totally independent from IL-2.

Our study using [^{3}H]thymidine showed no significant inhibition of the proliferation of PHA-activated lymphocytes by $1,25(OH)_2D_3$. Other investigators, however, found a marked inhibition of the lymphocyte proliferation by $1,25(OH)_2D_3$, as mentioned above (8, 9, 11). This discrepancy might be explained by the fact that the PBL in the other experiments were cultured for 72 h in the presence of PHA and $1,25(OH)_2D_3$, whereas in our study, [^{3}H]thymidine incorporation was determined at 48 h of culture. Our results suggest that the inhibition of GM-CSF production by $1,25(OH)_2D_3$ is not necessarily linked to its reported antiproliferative properties.

How does $1,25(OH)_2D_3$ regulate the expression of GM-CSF? In the case of glucocorticoids, studies showed that mouse mammary tumor virus DNA contains regions to which the glucocorticoid-receptor complex can specifically bind. Transcription is directly stimulated by interaction of the glucocorticoid-receptor complex with DNA sequences adjacent to the promoter (reviewed in reference 35). In a parallel fashion to the glucocorticoids, the $1,25(OH)_2D_3$ receptor complex might specifically bind to certain regions of DNA and inhibit the transcription of the GM-CSF gene either directly or via a transacting mechanism. Vanice et al., however, recently reported that dexamethasone regulated the expression of the alpha-1-acid glycoprotein at the posttranscriptional level (36). Preliminary experiments by us using in vitro nuclear run-on assays suggest that $1,25(OH)_2D_3$ affects the stability of GM-CSF mRNA.

In summary, our study shows that $1,25(OH)_2D_3$ inhibits sensitively the expression of GM-CSF by PBL and a HTLV-1 immortalized T lymphocyte line at the mRNA level. This down-regulation is mediated by a specific $1,25(OH)_2D_3$ receptor and can further occur independently of IL-2. We conclude that $1,25(OH)_2D_3$ might be important as a regulatory hormone in hematopoiesis.

Acknowledgments

We would like to thank Suzanne Bookstaver and Regina Simon for their excellent secretarial help, Dr. S. Clarke for generously providing the IL-2 cDNA, Dr. T. Nikaido for kindly providing the IL-2 receptor cDNA, Dr. J. Besemer for generously providing recombinant IL-2, and Dr. M. Uskokovic for kindly providing the vitamin D metabolites.

This work was supported by United States Public Health Service grants CA-26038, CA-32737, CA-33936, CA-30512, and CA-32428, the Dr. Murray Geisler Memorial Fund, the Louis Fagin Leukemia Research Foundation (Dr. Koeffler), AM-14,750-014 (Dr. Koeffler and Dr. Norman), the Deutsche Forschungsgemeinschaft (Dr. Reichel), CA-40136 (Dr. Gasson), and the Swiss and Bernese Cancer Ligues (Dr. Tobler).

References

1. Bell, N. H. 1985. Vitamin D-endocrine system. *J. Clin. Invest.* 76:1–6.

2. Manolagas, S. C., and L. J. Deftos. 1984. The vitamin D endocrine system and the hematolymphopoietic tissue. *Ann. Intern. Med.* 100:144–146.

3. Provvedini, D. M., C. D. Tsoukas, L. J. Deftos, and S. C. Manolagas. 1983. 1,25-dihydroxyvitamin D_3 receptors in human leukocytes. *Science (Wash. DC).* 221:1181–1183.

4. Bhalla, A. K., E. P. Amento, T. L. Clemens, M. P. Holick, and S. M. Krane. 1983. Specific high-affinity receptors for 1,25-dihydroxyvitamin D_3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. *J. Clin. Endocrinol. & Metab.* 57:1308–1310.

5. Koeffler, H. P., T. Amatruda, N. Ikekawa, Y. Kobayashi, and H. F. DeLuca. 1984. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D_3 and its fluorinated analogs. *Cancer Res.* 44:5624–5628.

6. Mangelsdorf, D. J., H. P. Koeffler, C. A. Donaldson, J. W. Pike, and M. R. Haussler. 1984. 1,25-dihydroxyvitamin D_3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. *J. Cell Biol.* 98:391–398.

7. Munker, R., A. W. Norman, and H. P. Koeffler. 1986. Vitamin D compounds: effects on clonal proliferation and differentiation of human myeloid cells. *J. Clin. Invest.* 78:424–430.

8. Lemire, J. M., J. S. Adams, V. Kermani-Arab, A. C. Bakke, R. Sakai, and S. C. Jordan. 1985. 1,25-dihydroxyvitamin D_3 suppresses human T helper/inducer lymphocyte activity in vitro. *J. Immunol.* 134: 3032–3035.

9. Rigby, W. F. C., T. Stacy, and M. W. Fanger. 1984. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D_3 (calcitriol). *J. Clin. Invest.* 74:1451–1455.

10. Tsoukas, C. D., D. M. Provvedini, and S. C. Manolagas. 1984. 1,25-dihydroxyvitamin D_3: a novel immunoregulatory hormone. *Science (Wash. DC).* 224:1438–1440.

11. Bhalla, A. K., E. P. Amento, B. Serog, and L. H. Glimcher. 1984. 1,25-dihydroxyvitamin D_3 inhibits antigen-induced T cell activation. *J. Immunol.* 113:1748–1754.

12. Adams, J. S., and M. A. Gacad. 1985. Characterization of 1α-hydroxylation of vitamin D_3 sterols by cultured alveolar macrophages from patients with sarcoidosis. *J. Exp. Med.* 161:755–765.

13. Koeffler, H. P., H. Reichel, J. E. Bishop, and A. W. Norman. 1985. γ-Interferon stimulates production of 1,25-dihydroxyvitamin D_3 by normal human macrophage. *Biochem. Biophys. Res. Commun.* 127: 596–603.

14. Cantrel, M. A., D. Anderson, D. P. Cerretti, V. Price, K. McKereghan, R. J. Tushinski, D. Y. Mochizuki, A. Larsen, K. Grabstein, S. Gillis, and D. Cosman. 1985. Cloning, sequence, and expression of a human granulocyte-macrophage colony-stimulating factor. *Proc. Natl. Acad. Sci. USA.* 82:6250–6254.

15. Wong, G. G., J. A. S. Witek, P. A. Temple, K. M. Wilkens, A. C. Leary, D. P. Luxenberg, S. S. Jones, E. L. Brown, R. M. Kay, E. C. Orr, C. H. Shoemaker, D. W. Golde, R. J. Kaufman, R. M. Hewick, E. A. Wang, and S. C. Clark. 1985. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. *Science (Wash. DC).* 228:810–815.

16. Tomonaga, M., D. W. Golde, and J. C. Gasson. 1986. Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemic cell lines. *Blood.* 67: 31–36.

17. Sieff, C. A., S. G. Emerson, R. E. Donahue, D. G. Nathan, E. A. Wang, G. G. Wong, and S. C. Clark. 1985. Recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. *Science (Wash. DC).* 230:1171–1173.

18. Gasson, J. C., R. H. Weissbart, S. E. Kaufman, S. C. Clark, R. M. Hewick, G. G. Wong, and D. W. Golde. 1984. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. *Science (Wash. DC).* 226:1339–1342.

19. Weisbart, R. H., D. W. Golde, S. C. Clark, G. G. Wong, and J. C. Gasson. 1985. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. *Nature.* 314:361–363.

20. Koeffler, H. P., I. S. Y. Chen, and D. W. Golde. 1984. Characterization of a novel HTLV-infected cell line. *Blood.* 64:482–490.

21. Colline, S. J., R. C. Gallo, and R. E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. *Nature (Lond.).* 270:347–349.

22. Koeffler, H. P., and D. W. Golde. 1978. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. *Science (Wash. DC).* 200:1153–1154.

23. Golde, D. W., S. G. Quan, and M. J. Cline. 1978. Human T lymphocyte cell line producing colony-stimulating activity. *Blood.* 52: 1068–1072.

24. Clark, S., S. K. Arya, F. Wong-Staal, M. Matsumoto-Kobayashi, R. M. Kay, R. J. Kaufman, E. L. Brown, C. Shoemaker, T. Copeland, S. Oroszlan, K. Smith, M. G. Sarngadharan, S. G. Lindner, and R. C. Gallo. 1984. Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. *Proc. Natl. Acad. Sci. USA.* 81:2543–2547.

25. Nikaido, T., A. Shimizu, N. Ishida, H. Sabe, K. Teshigawara, M. Maeda, T. Uchiyama, J. Yodoi, and T. Honjo. 1984. Molecular cloning of cDNA encoding human interleukin-2 receptor. *Nature (Lond.).* 311: 631–635.

26. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:6–13.

27. Maniatis, T., E. P. Fritsch, and J. Sambrook. 1982. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY. 109–112.

28. Clemens, M. J. 1984. Purification of eukariotic mRNA. *In* Transcription and Translation. B. D. Hames and S. J. Higgins, editors. IRL Press, Washington. 211–220.

29. Uchiyama, T., T. Hori, M. Tsudo, Y. Wano, H. Umadome, S. Tamori, J. Yodoi, M. Maeda, H. Sawami, and H. Uchino. 1985. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. *J. Clin. Invest.* 76:446–453.

30. Waldmann, T. A. 1986. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. *Science (Wash. DC).* 232:727–732.

31. Proscal, D. A., W. H. Okamura, and A. W. Norman. 1976. Vitamin D, its metabolites and analogs: a review of the structural requirements for biological activity. *Am. J. Clin. Nutr.* 29:1271–1282.

32. Koren, R., A. Ravid, U. A. Liberman, Z. Hochberg, Y. Weisman, and A. Novogrodsky. 1985. Defective binding and function of 1,25-dihydroxyvitamin D_3 receptors in peripheral mononuclear cells of patients with end-organ resistance to 1,25-dihydroxyvitamin D. *J. Clin. Invest.* 76:2012–2015.

33. Arya, S. K., F. Wong-Staal, and R. C. Gallo. 1984. T-cell growth factor gene: lack of expression in human T-cell leukemia-lymphoma virus-infected cells. *Science (Wash. DC).* 223:1086–1087.

34. Lemire, J. M., J. S. Adams, R. Sakai, and S. C. Jordan. 1984. 1α,25-dihydroxyvitamin D_3 suppresses proliferation and immunglobulin production by normal human peripheral blood mononuclear cells. *J. Clin. Invest.* 74:657–661.

35. Ringold, G. M. 1983. Regulation of mouse mammary tumor virus gene expression by glucocorticoid hormones. *Curr. Top. Microbiol. Immunol.* 106:79–103.

36. Vanice, J. L., J. M. Taylor, and G. M. Ringold. 1984. Glucocorticoid-mediated induction of alpha 1-acid glycoprotein: evidence for hormone-regulated processing. *Proc. Natl. Acad. Sci. USA.* 81:4241–4245.